Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia

References

• Fielding AK, Richards SM, Chopra R, . Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007;109:944–950.
   PubMed Web of Science ®Google Scholar
• Faderl S, O’Brien S, Pui C-H, . Adult acute lymphoblastic leukemia. Cancer 2010;116:1165–1176.
   PubMed Web of Science ®Google Scholar
• FitzGerald DJ, Wayne AS, Kreitman RJ, . Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res 2011;71:6300t–6309.
   PubMed Web of Science ®Google Scholar
• Schindler J, Sausville E, Messmann R, . The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. Clin Cancer Res 2001;7:255–258.
   PubMed Web of Science ®Google Scholar
• Messmann RA, Vitetta ES, Headlee D, . A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma. Clin Cancer Res 2000;6:1302–1313.
   PubMed Web of Science ®Google Scholar
• Jegalian AG, Wayne AS, Kreitman RJ, . CD22 expression in pediatric B-lineage acute lymphoblastic leukemia. Blood 2009;114(Suppl. 1): Abstract 4119.
   Google Scholar
• May RD, Vitetta ES, Moldenhauer G, . Selective killing of normal and neoplastic human B cells with anti-CD19- and anti-CD22-ricin A chain immunotoxins. Cancer Drug Deliv 1986;3:261–272.
   PubMedGoogle Scholar
• Herrera L, Bostrom B, Gore L, . A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2009;31:936–941.
   PubMed Web of Science ®Google Scholar
• Topp MS, Zugmaier G, Goekbuget N, . Report of a phase II trial of single-agent BiTE(R) antibody blinatumomab in patients with minimal residual disease (MRD) positive B-precursor acute lymphoblastic leukemia (ALL). Blood 2009;114(Suppl. 1): Abstract 840.
   PubMed Web of Science ®Google Scholar
• Topp MS, Kufer P, Gökbuget N, . Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29:2493–2498.
   PubMed Web of Science ®Google Scholar
• Dominietto A, Raiola AM, Van Lint MT, . Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br J Haematol 2001;112:219–227.
   PubMed Web of Science ®Google Scholar
• Jabbour E, O’Brien S, Thomas D, . Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse (R-R) acute lymphocytic leukemia (ALL). J Clin Oncol 2011;29(Suppl.): Abstract 6507.
   Google Scholar
• Schindler J, Gajavelli S, Ravandi F, . A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia. Br J Haematol 2011;154:471–476.
   PubMed Web of Science ®Google Scholar
• Herrera L, Farah RA, Pellegrini VA, . Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia 2000;14:853–858.
   PubMed Web of Science ®Google Scholar
• Ghetie MA, Podar EM, Gordon BE, . Combination immunotoxin treatment and chemotherapy in SCID mice with advanced, disseminated Daudi lymphoma. Int J Cancer 1996;68:93–96.
   PubMed Web of Science ®Google Scholar
• Herrera L, Stanciu-Herrera C, Morgan C, . Anti-CD19 immunotoxin enhances the activity of chemotherapy in severe combined immunodeficient mice with human pre-B acute lymphoblastic leukemia. Leuk Lymphoma 2006;47:2380–2387.
   PubMed Web of Science ®Google Scholar
• Griffin TC, Weitzman S, Weinstein H, . A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20 +) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 2009;52:177–181.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Österborg A, . CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Oriol A, Ribera JM, Bergua J, . High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer 2008;113:117–125.
   PubMed Web of Science ®Google Scholar
• Corazzelli G, Frigeri F, Russo F, . RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and “unclassifiable” highly aggressive B-cell lymphoma. Br J Haematol 2012;156:234–244.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Faderl S, O’Brien S, . Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006;106:1569–1580.
   PubMed Web of Science ®Google Scholar
• Raponi S, Stefania De Propris M, Intoppa S, . Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma 2011;52:1098–1107.
   PubMed Web of Science ®Google Scholar
• Ghetie M-A, May RD, Till M, . Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy. Cancer Res 1988;48:2610–2617.
   PubMed Web of Science ®Google Scholar
• Herrera L, Yarbrough S, Ghetie V, . Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins. Leukemia 2003;17:334–338.
   PubMed Web of Science ®Google Scholar
• de Vries JF, Zwaan CM, De Bie M, . The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia 2012;26:255–264.
   PubMed Web of Science ®Google Scholar
• Liu X-Y, Pop LM, Tsai L, . Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines. Int J Cancer 2011;129:497–506.
   Google Scholar
• Dreier T, Baeuerle PA, Fichtner I, . T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol 2003;170:4397–4402.
   PubMed Web of Science ®Google Scholar
• Stanciu-Herrera C, Morgan C, Herrera L. Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in pre-B acute lymphoblastic leukemia cell lines. Leuk Res 2008;32:625–632.
   PubMed Web of Science ®Google Scholar
• Advani A, Gundacker H, Sala-Torra O, . Southwest Oncology Group study S0530: a phase 2 trial of clofarabine/cytarabine for relapsed/ refractory acute lymphocytic leukemia. Blood 2009;114(Suppl. 1): Abstract 3094.
   Google Scholar
• Larson RA, Dodge RK, Linker CA, . A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 1998;92:1556–1564.
   PubMed Web of Science ®Google Scholar
• Ludwig W-D, Rieder H, Bartram CR, . Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89. Blood 1998;92:1898–1909.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Buck G, Burnett AK, . Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005;106:3760–3767.
   PubMed Web of Science ®Google Scholar
• Ribera J, Oriol A, Bethencourt C, . Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica 2005;90:1346–1356.
   PubMed Web of Science ®Google Scholar
• Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011;29:532–543.
   PubMed Web of Science ®Google Scholar